Bank of New York Mellon’s ACELYRIN SLRN Stock Holding History

Bank of New York Mellon’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-173,277	Closed	-$428K	–	4252
2025 Q1	$428K	Sell	173,277 -3,622	-2%	-$8.61K	﹤0.01%	3526
2024 Q4	$555K	Buy	176,899 +684	+0.4%	+$3.31K	﹤0.01%	3467
2024 Q3	$869K	Sell	176,215 -47,180	-21%	-$244K	﹤0.01%	3218
2024 Q2	$985K	Buy	223,395 +41,058	+23%	+$192K	﹤0.01%	3211
2024 Q1	$1.23M	Buy	182,337 +86,627	+91%	+$658K	﹤0.01%	3037
2023 Q4	$714K	Buy	95,710 +3,009	+3%	+$25.7K	﹤0.01%	3361
2023 Q3	$943K	Buy	92,701 +79,478	+601%	+$1.69M	﹤0.01%	3197
2023 Q2	$276K	Buy	+13,223	New	+$270K	﹤0.01%	3870

Other funds holding SLRN

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Bank of New York Mellon's SLRN Position: Q2 2025 in Review

Bank of New York Mellon sold out of ACELYRIN (SLRN) in Q2 2025, closing a stake of 173,277 shares — an estimated $428K sold.

Bank of New York Mellon first reported a position in SLRN in Q2 2023 and held it in 8 quarters. The position peaked at $1.23M in Q1 2024. 2 funds tracked by Wall St. Rank hold SLRN as of Q2 2025.

Bank of New York Mellon reported no remaining ACELYRIN position as of Q2 2025 after selling out during the quarter.
Bank of New York Mellon sold 173,277 ACELYRIN shares in Q2 2025, an estimated $428K.
Bank of New York Mellon first reported a position in ACELYRIN in Q2 2023 and held it in 8 quarters.
Bank of New York Mellon's ACELYRIN position peaked at $1.23M in Q1 2024.
2 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2025.

Based on Bank of New York Mellon's 13F filing for Q2 2025, filed 5 Aug 2025.